• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Merck gets FDA nod for skin cancer drug

      Posted Atreuters.com

      Merck & Co Inc said the U.S. health regulator approved its drug to treat skin cancer in patients with node-positive melanoma, following removal of the affected part.

      Merck's drug Sylatron, which is delivered by a subcutaneous injection, is indicated as an additional treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection.

      The company said patients with a history of severe allergic reaction to hepatitis C drugs peginterferon alfa-2b or interferon alfa-2b should not use Sylatron.

      Merck said the approval of the drug is based on data from the European Organisation for the Research and Treatment of Cancer.

      April 15, 2011


       

      Share this Article!

    Back to top^